In a nutshell
This study aimed to evaluate a minimally invasive surgical treatment option for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). This study found that the temporary implantable nitinol device (iTIND) is a promising technique for these patients.
Some background
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland. BPH can impede the flow of urine. This leads to lower urinary tract symptoms (LUTS) such as dribbling of urine and a feeling of incomplete bladder emptying. This can have a poor effect on the quality of life. One surgical option is the temporary implantable nitinol device (iTIND). An earlier version of this treatment option is the TIND. This device is implanted into the urethra (the tube that urine passes through). It exerts pressure on the prostate, widening it. It is taken out after a few days.
Its effectiveness is still under investigation.
Methods & findings
This study analyzed the results of 3 other articles about TIND and iTIND in patients with BPH-related LUTS. The functional outcomes were analyzed.
Both the TIND and iTIND implantations were safe, effective, and well-tolerated procedures. Side-effects included blood in urine, pain and painful urination. These were usually in the short-term. The overall quality of life and symptom score improved from 3 to 12 months after the surgery and no patients required additional surgical treatments.
The bottom line
This study found that iTIND is a promising technique in patients with BPH-related LUTS.
The fine print
This study included 3 other studies with different protocols. A large study with a long follow-up period is needed for stronger evidence.
Published By :
Current urology reports
Date :
Jul 05, 2019
